Catalog No.
YHC85101
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Thr110-Asn241
Predicted molecular weight
17.43 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P11049
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
CD37, Tspan-26, TSPAN26, Leukocyte antigen CD37, Tetraspanin-26
CD37 regulates the self-renewal of leukemic stem cells via integrin-mediated signaling in acute myeloid leukemia., PMID:40250439
Tetraspanin CD37 regulates platelet hyperreactivity and thrombosis., PMID:40126944
Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy., PMID:39673705
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas., PMID:39374583
CD37 in acute myeloid leukemia: a novel surface target for drug delivery., PMID:39348689
[Prognostic value and imaging features of (18)F-FDG PET-CT in follicular lymphoma with different histopathology grade]., PMID:39307726
Anti-CD37 CAR T cells: another arrow in the quiver., PMID:39264608
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies., PMID:38846084
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies., PMID:38781564
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia., PMID:38754420
Identification of triciribine as a novel myeloid cell differentiation inducer., PMID:38743735
Proximity-Based Labeling Identifies MHC Class II and CD37 as B Cell Receptor-Proximal Proteins with Immunological Functions., PMID:38625120
Diagnostic value of sphingolipid metabolism-related genes CD37 and CXCL9 in nonalcoholic fatty liver disease., PMID:38394483
Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials., PMID:38041957
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma., PMID:38035078
N-Glycosylation-dependent regulation of immune-specific tetraspanins CD37 and CD53., PMID:38031400
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine., PMID:38014209
Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models., PMID:37828726
β-Lapachone Exerts Anticancer Effects by Downregulating p53, Lys-Acetylated Proteins, TrkA, p38 MAPK, SOD1, Caspase-2, CD44 and NPM in Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells., PMID:37373014
Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer., PMID:37284741
The Impact of CD37 Ectoenzyme Expression in Benign and Malignant Colorectal Tumors., PMID:37274903
The evaluation of CD39, CD73, and HIF-1 α expression besides their related miRNAs in PBMCs of women with recurrent pregnancy loss., PMID:36758470
Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa., PMID:36481267
Isolation of a cytolytic subpopulation of extracellular vesicles derived from NK cells containing NKG7 and cytolytic proteins., PMID:36189227
Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37., PMID:36100608
Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome., PMID:35914223
Absence of toxin gene transfer from Clostridioides difficile strain 630Δerm to nontoxigenic C. difficile strain NTCD-M3r in filter mating experiments., PMID:35767545
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?, PMID:35486292
89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma., PMID:35428777
CD37 expression in follicular lymphoma., PMID:35171311
Identification of immune-related cells and genes in the breast invasive carcinoma microenvironment., PMID:35120331
IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma., PMID:35086136
[Expression of RASGRP2 in Lung Adenocarcinoma and Its Effect
on Immune Microenvironment]., PMID:34157800
Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells., PMID:34099546
Transcriptome profiles discriminate between Gram-positive and Gram-negative sepsis in preterm neonates., PMID:33767373
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia., PMID:33683501
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma., PMID:33652767
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:33523334
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies., PMID:33333768
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma., PMID:33259039
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma., PMID:33196921
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma., PMID:32877524
Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma., PMID:32616892
Cathelicidin-Related Antimicrobial Peptide Regulates CD73 Expression in Mouse Th17 Cells via p38., PMID:32604872
CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia., PMID:32400873
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies., PMID:32341336
Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors., PMID:32231196
CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer., PMID:32205841
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003., PMID:32187209
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma., PMID:32172489
For research use only. Not for human or drug use.
